Please login to the form below

Not currently logged in
Email:
Password:

NDA Group names general manager of new Switzerland operation

Stephanie Krumholz-Bahner has held numerous senior roles

Drug development, pharmacovigilance and HTA consultancy NDA Group has named Stephanie Krumholz-Bahner as general manager of its new Swiss operation.

The arm, named NDA Regulatory Service Switzerland, will support NDA's global client base with a specific focus on Swiss development requirements, in addition to aiding its clients in the area with global drug development needs.

Krumholz-Bahner has expansive experience in the pharma industry, holding senior roles in European, US and international regulatory affairs at Roche and Cytos across multiple therapeutic areas, including metabolic, oncology and inflammation.

Commenting on her appointment, she said: “I am delighted to be joining NDA Group and leading the new operation in Switzerland. NDA is committed to supporting global regulatory strategies and submissions for our clients with a natural addition of Swiss specific expertise.

“This will also enable clients in the region to more easily engage in our global capabilities through our involvement in the Zurich area.”

Prior to joining the pharma industry, Krumholz-Bahner was a pharmacological consultant for a venture capital company.

Johan Strömquist, CEO of NDA Group, added: “Stephanie's diverse and extensive experience as well as her growing network of contacts in Switzerland and beyond will be a tremendous asset for our client to tap in to.

“Stephanie will serve as another perfect conduit for our clients into the broader capabilities of the NDA Group.”

19th March 2015

From: Regulatory

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics